Phase III Radium 223 mCRPC-PEACE III
UNICANCER
Cliniques Universitaires de Saint Luc

      The objective of this randomized phase III open label trial is to assess if upfront
      combination of enzalutamide and Ra223 improves radiological progression-free survival
      compared to enzalutamide single agent in asymptomatic or mildly symptomatic castration
      resistant prostate cancer patients metastatic to bone.
    
Drug